Detection of CH using 48-myeloid cancer gene panel. (A) Mutation profiles by participants. (B) The types of mutations and their frequencies in CH-associated genes (orange = frameshift; purple = splice site; green = non–frameshift indel; blue = nonsense; red = missense). (C) Percentage of participants with at least 1 mutation in TET2, in both TET2+DNMT3A, in DNMT3A, or only in another gene.